Loading
Biogen Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 17 Feb 2026.
Biogen Inc.: what insiders have been doing
This page follows insider dealings at Biogen Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Cambridge, United States. The group dates from 1978. In the past year (18 October 2025 to 18 October 2026), 38 filings came from 20 insiders.
No insider sold shares on the market over the period. Instead, the filings list 1 purchase totalling €493, made by 1 insider. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Those buying include 1 senior executive. One trade stands out by size: a purchase of €493 from Murphy Nicole, disclosed on 17 February 2026.
Across the 5,808 companies tracked on its exchange, the median is 19 filings; at 38 filings, this issuer sits above that mark. Since 2016, the database holds 3 purchases and 15 sales by insiders of the company. The 10-K for the year ended 31 December 2025 shows 9.89 bn USD of revenue and 1.29 bn USD of net income.
The last purchase on record was published on 17 February 2026, which is 243 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. US insiders must file a Form 4 within two business days of a trade.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
237
Thresholds
n/a
Buy Volume
€229,005
3 ops. · all time
Sell Volume
€10M
15 ops. · all time
Who traded when
BuySaleMinor Lloyd2 sales
Priya Singhal2 sales
Dorsa Caroline1 buy
Nicole Murphy1 buy
Rachid Izzar1 sale
Stephen A. Sherwin1 sale
Since the insiders bought
- -1.8%Entry US$194.13 · Close at T+90 US$190.56
- +63.2%Entry US$116.82 · Close at T+365 US$190.68
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Biogen Inc. Buy (bullish), based on 32 analysts. Average price target: US$243.98.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 9,233 of 24,148 companies
57.4
score / 100
Value52
Quality62
FCF yld5.7%
Earn yld3.7%
EV/EBITDA15.9x
ROE4.6%
Gross mgn76%
Net mgn13%
Debt/EBITDA2.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$229.41
Analyst consensus
32 analystsBuy
US$175.00Target US$243.98(+6%)US$300.00
Income statement
RevenueUS$9.9B
Gross profitUS$7.5B76% margin
EBITDAUS$2.6B26% margin
Net incomeUS$1.3B8.3% margin
Valuation
PER (trailing)41.4x
PER (forward)13.9x
P/Book1.8x
Beta0.09
Balance sheet & cash
Market capUS$33.9B
Total debtUS$6.6B
Free Cash FlowUS$2B
Debt / Equity44%
Profitability & ownership
ROE4.6%
ROA5.2%
% insiders0.2%
% institutions99.5%
Last declaration on 5 October 2026
Declarations237 total
27 shares0Common StockSEC:0000875045-26-000084:0
8 shares@ US$219.880.0000% mcap15.5% of flowCommon StockSEC:0000875045-26-000084:1
593 shares@ US$200.960.0004% mcap49.7% of flowCommonSEC144:0001959173-26-005582
593 shares@ US$203.340.0004% mcap50.3% of flowCommonSEC144:0001959173-26-005518
1,505 sharesCommon StockSEC:0000875045-26-000055:1
1,505 sharesCommon StockSEC:0000875045-26-000059:0
1,505 sharesCommon StockSEC:0000875045-26-000062:0
1,505 sharesCommon StockSEC:0000875045-26-000064:0
2,005 sharesCommon StockSEC:0000875045-26-000052:0
1,505 sharesCommon StockSEC:0000875045-26-000054:0
2,370 sharesCommon StockSEC:0000875045-26-000055:0
1,505 sharesCommon StockSEC:0000875045-26-000060:0
1,505 sharesCommon StockSEC:0000875045-26-000065:0
1,505 sharesCommon StockSEC:0000875045-26-000063:0
939 shares0Common StockSEC:0000875045-26-000046:0
455 shares@ US$187.060.0003% mcap100.0% of flowCommon StockSEC:0000875045-26-000046:1
54 shares@ US$183.78100.0% of flowCommon StockSEC:0000875045-26-000036:1
181 shares0Common StockSEC:0000875045-26-000036:0
3 shares@ US$195.0354.3% of flowCommon StockSEC:0000875045-26-000033:0
Canonical exit: 13 May 2026 (T+90)
9,008 shares0Common StockSEC:0000875045-26-000024:0
2,217 shares0Common StockSEC:0000875045-26-000023:0
2,102 shares0Common StockSEC:0000875045-26-000022:0
789 shares0Common StockSEC:0000875045-26-000021:0
2,044 shares0Common StockSEC:0000875045-26-000019:0
1,635 shares0Common StockSEC:0000875045-26-000017:0
25 of 237 declarations
About Biogen Inc.
Biogen Inc. (ticker: BIIB) is a U.S.-listed biotechnology company traded on the NASDAQ market in the United States, with headquarters in Cambridge, Massachusetts. Founded in 1978, Biogen is one of the oldest independent American biotech companies and has built its identity around neuroscience, immunology, and, more recently, rare diseases. For investors, the company is best understood as a specialty biopharma platform focused on complex, high-unmet-need conditions rather than broad mass-market therapeutics.
Biogen’s legacy was established in multiple sclerosis, where it became a long-standing pioneer and still maintains a broad, commercially important portfolio. Over time, the company expanded beyond MS into central nervous system and neurodegenerative diseases, including Alzheimer’s disease, as well as other neuroscience and rare-disease areas. Its current strategy combines internal R&D with targeted business development to strengthen its product franchise, broaden its therapeutic reach, and sustain long-term growth. Key commercial and pipeline themes include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, and selected rare-disease and immunology programs. Biogen also continues to invest in next-generation therapies and delivery technologies designed to improve treatment convenience and patient access.
Read moreShow less
From a competitive standpoint, Biogen operates in highly contested therapeutic categories where differentiation depends on clinical data, regulatory execution, physician adoption, and reimbursement dynamics. Its main advantages are deep scientific expertise in neurology, a long operating history in specialty commercialization, and an international footprint. According to company disclosures, its therapies are available in more than 80 countries, and the company maintains major U.S. research, manufacturing, and operational hubs, especially in Cambridge and North Carolina. That U.S. industrial base remains an important part of the company’s execution model.
Recent strategic developments have centered on the Alzheimer’s franchise and portfolio reshaping. Biogen and its partner Eisai have continued to advance LEQEMBI, including new dosing and delivery options aimed at broadening the treatment experience for early Alzheimer’s disease. The company has also pushed forward new pipeline assets, including tau-targeting approaches, while strengthening its rare-disease and immunology profile. In March 2026, Biogen announced an agreement to acquire Apellis, a move intended to expand its growth portfolio, add commercial products, and accelerate entry into nephrology. For equity investors, these steps suggest a company trying to offset mature legacy franchises with a more diversified next phase of growth.
Overall, Biogen remains a major specialty biotech name with meaningful scale, strong neuroscience heritage, and a market position anchored in the United States. Its NASDAQ listing, Cambridge headquarters, and strategic focus on difficult-to-treat diseases make it a closely watched healthcare stock for long-term investors.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
